Edesa Biotech, Inc.
NASDAQ:EDSABiotechnology
+$0.09 today
- Market cap
- $55.39M
- Beta
- 1.07
- P/E (TTM)
- -5.5
- EPS (TTM)
- -$1.27
Volume 0.07M
Average 0.62M
EDSA Investing Cash Flow
Net cash used in or generated by investments in assets, acquisitions, and securities.
Edesa Biotech, Inc.NASDAQ: EDSA
Investing Cash Flow · Q2 FY2026 · quarter ended Mar 2026
Investing cash flow outflow grows to $0
Q2 FY2026 investing cash flow was $0, compared with $0 a year earlier. Trailing-twelve-month investing cash flow was $0.
Context
- Investing cash flow increased in 1 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly investing cash flow holds near $0 or moves back toward the trailing-twelve-month quarterly average of $0.
Sources:Cash FlowText generated from reported figures; not investment advice.
Investing Cash Flow history
USD · from the cash flow
- Latest · FY2025
- 0 USD
- Year-over-year change
- —
| Period | Period end | Investing Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-09-30 | 0 | — |
| FY2024 | 2024-09-30 | 0 | — |
| FY2023 | 2023-09-30 | 0 | +100.0% |
| FY2022 | 2022-09-30 | (5.66K) | +8.0% |
| FY2021 | 2021-09-30 | (6.15K) | — |
Investing Cash Flow vs competitors
How EDSA compares with its peers on the latest reported figures
- EDSA's LTM Mar 2026 investing cash flow of $0 is the largest of the 2 companies compared; the peer median is $0.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $0 | — | — | — | |
| LTM Mar 2026 | $0 | -100.0% | — | — | |
| Peer median (excluding EDSA) | $0 | -100.0% | — | — | |
Competitors are the stored peer set for EDSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Sep 2021 | FY2022 Sep 2022 | FY2023 Sep 2023 | FY2024 Sep 2024 | FY2025 Sep 2025 |
|---|---|---|---|---|---|
| Net Income | (13.34M) | (17.55M) | (8.37M) | (6.17M) | (7.19M) |
| Depreciation & Amortization | 118.79K | 118.19K | 183.47K | 186.05K | 119.27K |
| Deferred Income Tax | (3.31M) | (2.38M) | (308K) | 0 | 0 |
| Stock-Based Compensation | 3.2M | 2.26M | 1.25M | 537.49K | 729.64K |
| Change in Working Capital | (3.64M) | 2.89M | 308K | 571.07K | (985.65K) |
| Accounts Receivables | (3.23M) | 2.03B | 562.77K | 356.34K | (377.99K) |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (124.72K) | 882.84K | (556.27K) | 0 | 0 |
| Other Working Capital | (281.36K) | (2.03B) | 301.5K | 214.73K | (607.67K) |
| Other Non-Cash Items | 3.31M | 2.38M | 308K | (14.77K) | 0 |
| Operating Cash Flow | (13.66M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
| Capital Expenditures | (6.15K) | (5.66K) | 3 | 0 | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | (3) | 0 | 0 |
| Investing Cash Flow | (6.15K) | (5.66K) | 0 | 0 | 0 |
| Debt Repayment | 0 | 0 | 0 | (29.53K) | 0 |
| Common Stock Issued | 14.17M | 11.63M | 4.83M | 621.56K | 17.03M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 14.17M | 11.63M | 4.83M | 592.03K | 17.03M |
| Effect of Forex Changes | 121.9K | (93.01K) | 76.85K | (25.9K) | 46.22K |
| Net Change in Cash | 625.56K | (748.34K) | (1.73M) | (4.32M) | 9.75M |
| Free Cash Flow | (13.67M) | (12.28M) | (6.64M) | (4.89M) | (7.32M) |
Edesa Biotech, Inc.
NASDAQ:EDSA
Intrinsic Alpha fair value
Locked
Current Price
$5.75
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.